JP2007512243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512243A5 JP2007512243A5 JP2006538514A JP2006538514A JP2007512243A5 JP 2007512243 A5 JP2007512243 A5 JP 2007512243A5 JP 2006538514 A JP2006538514 A JP 2006538514A JP 2006538514 A JP2006538514 A JP 2006538514A JP 2007512243 A5 JP2007512243 A5 JP 2007512243A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- composition
- dose
- weekly
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010002350 Interleukin-2 Proteins 0.000 claims 131
- 102000000588 Interleukin-2 Human genes 0.000 claims 131
- 230000003442 weekly effect Effects 0.000 claims 77
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 230000027455 binding Effects 0.000 claims 46
- 239000012634 fragment Substances 0.000 claims 46
- 239000005557 antagonist Substances 0.000 claims 26
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 208000003950 B-cell lymphoma Diseases 0.000 claims 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 210000004408 hybridoma Anatomy 0.000 claims 7
- 229950004563 lucatumumab Drugs 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 230000003325 follicular Effects 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 4
- 108010063916 CD40 Antigens Proteins 0.000 claims 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 2
- 201000003791 MALT lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000012875 competitive assay Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 210000005170 neoplastic cell Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51733703P | 2003-11-04 | 2003-11-04 | |
| US60/517,337 | 2003-11-04 | ||
| US52557903P | 2003-11-26 | 2003-11-26 | |
| US60/525,579 | 2003-11-26 | ||
| US56571004P | 2004-04-27 | 2004-04-27 | |
| US60/565,710 | 2004-04-27 | ||
| PCT/US2004/036958 WO2005044294A2 (en) | 2003-11-04 | 2004-11-04 | Method of therapy for cancers expressing the cd40 antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011033969A Division JP2011126900A (ja) | 2003-11-04 | 2011-02-18 | Ｃｄ４０抗原を発現する癌に対する治療方法。 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007512243A JP2007512243A (ja) | 2007-05-17 |
| JP2007512243A5 true JP2007512243A5 (enExample) | 2007-12-13 |
| JP4765039B2 JP4765039B2 (ja) | 2011-09-07 |
Family
ID=34577667
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538514A Expired - Fee Related JP4765039B2 (ja) | 2003-11-04 | 2004-11-04 | Ｃｄ４０抗原を発現する癌に対する治療方法。 |
| JP2006538513A Expired - Lifetime JP4746552B2 (ja) | 2003-11-04 | 2004-11-04 | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
| JP2006538540A Expired - Lifetime JP5019881B2 (ja) | 2003-11-04 | 2004-11-04 | アンタゴニスト抗ｃｄ４０モノクローナル抗体およびそれらを使用するための方法 |
| JP2010277537A Withdrawn JP2011072317A (ja) | 2003-11-04 | 2010-12-13 | アンタゴニスト抗ｃｄ４０モノクローナル抗体およびそれらを使用するための方法 |
| JP2011033969A Withdrawn JP2011126900A (ja) | 2003-11-04 | 2011-02-18 | Ｃｄ４０抗原を発現する癌に対する治療方法。 |
| JP2011040922A Withdrawn JP2011105769A (ja) | 2003-11-04 | 2011-02-25 | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538513A Expired - Lifetime JP4746552B2 (ja) | 2003-11-04 | 2004-11-04 | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
| JP2006538540A Expired - Lifetime JP5019881B2 (ja) | 2003-11-04 | 2004-11-04 | アンタゴニスト抗ｃｄ４０モノクローナル抗体およびそれらを使用するための方法 |
| JP2010277537A Withdrawn JP2011072317A (ja) | 2003-11-04 | 2010-12-13 | アンタゴニスト抗ｃｄ４０モノクローナル抗体およびそれらを使用するための方法 |
| JP2011033969A Withdrawn JP2011126900A (ja) | 2003-11-04 | 2011-02-18 | Ｃｄ４０抗原を発現する癌に対する治療方法。 |
| JP2011040922A Withdrawn JP2011105769A (ja) | 2003-11-04 | 2011-02-25 | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
Country Status (22)
| Country | Link |
|---|---|
| EP (6) | EP1682178B8 (enExample) |
| JP (6) | JP4765039B2 (enExample) |
| KR (2) | KR101403910B1 (enExample) |
| CN (2) | CN1905897B (enExample) |
| AT (3) | ATE447412T1 (enExample) |
| AU (3) | AU2004287482B2 (enExample) |
| CA (3) | CA2544853C (enExample) |
| CY (3) | CY1110231T1 (enExample) |
| DE (3) | DE602004028037D1 (enExample) |
| DK (4) | DK1682180T3 (enExample) |
| EC (2) | ECSP066607A (enExample) |
| ES (3) | ES2435410T3 (enExample) |
| HR (2) | HRP20100066T1 (enExample) |
| IL (1) | IL175225A (enExample) |
| MA (1) | MA28331A1 (enExample) |
| PL (4) | PL1682180T3 (enExample) |
| PT (4) | PT1682180E (enExample) |
| RS (2) | RS53073B (enExample) |
| SG (1) | SG148143A1 (enExample) |
| SI (3) | SI1682180T1 (enExample) |
| WO (3) | WO2005044294A2 (enExample) |
| ZA (1) | ZA200604419B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| RS53073B (sr) * | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| PT1684869E (pt) * | 2003-11-04 | 2011-09-16 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros relacionados com células b |
| WO2005108428A2 (en) * | 2004-02-26 | 2005-11-17 | Compugen Ltd. | Cd40 splice variants and their uses |
| JP5421590B2 (ja) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| RU2442606C2 (ru) * | 2005-11-01 | 2012-02-20 | Новартис Аг | Применение анти-cd40-антител |
| AU2006308606C1 (en) * | 2005-11-01 | 2013-07-25 | Novartis Ag | Uses of anti-CD40 antibodies |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| BR122021001906B1 (pt) | 2005-12-09 | 2022-03-29 | Kling Biotherapeutics B.V. | Método para aumentar a estabilidade de uma célula produtora de anticorpo, método para produzir uma célula produtora de anticorpo que é estável durante pelo menos uma semana, método para produzir linhagem de células b, e método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse |
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| GEP20125628B (en) * | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CA2692165A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| BRPI0820707A2 (pt) * | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| JP5559695B2 (ja) * | 2007-11-09 | 2014-07-23 | ノバルティス アーゲー | 抗ｃｄ４０抗体の使用 |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US9617600B2 (en) | 2009-04-18 | 2017-04-11 | Genentech, Inc. | Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| ES2666584T3 (es) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| AU2016201742B2 (en) * | 2010-11-15 | 2017-11-02 | Novartis Ag | Silent Fc variants of anti-CD40 antibodies |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| PT2646466T (pt) | 2010-12-02 | 2017-06-07 | Aimm Therapeutics Bv | Meios e métodos para produzir anticorpos de alta afinidade |
| ES2734076T3 (es) * | 2011-02-17 | 2019-12-04 | Kyowa Hakko Kirin Co Ltd | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada |
| US9713636B2 (en) * | 2011-02-28 | 2017-07-25 | Napajen Pharma, Inc. | Nucleic acid/polysaccharide complex |
| HUE065915T2 (hu) | 2011-03-11 | 2024-06-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásaik |
| US9475879B2 (en) * | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| SG11201401360XA (en) | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
| US9624310B2 (en) | 2011-11-17 | 2017-04-18 | Gundram Jung | Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells |
| US11078265B2 (en) * | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| EP2914627B1 (en) * | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| CA2891764A1 (en) | 2012-11-19 | 2014-05-22 | Baliopharm Ag | Recombinant bispecific antibody binding to cd20 and cd95 |
| US20160151486A1 (en) * | 2013-06-13 | 2016-06-02 | Fast Foward Pharmaceuticals B.V. | CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis |
| WO2015115892A1 (en) | 2014-01-31 | 2015-08-06 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
| US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
| CN108025068A (zh) * | 2014-03-12 | 2018-05-11 | 耶达研究与开发有限公司 | 降低系统性调节性t细胞水平或活性来治疗cns的疾病和损伤 |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| KR20160124912A (ko) * | 2014-03-19 | 2016-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| BR112017014684A2 (en) | 2015-02-04 | 2018-01-09 | Boehringer Ingelheim International Gmbh | methods of treatment of inflammatory diseases |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| EP3334747B1 (en) | 2015-08-13 | 2023-09-27 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
| EP3307322B1 (en) | 2015-09-04 | 2021-02-17 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| MX2018003905A (es) | 2015-09-30 | 2018-09-06 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso. |
| EP3445783A2 (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| CN110267989B (zh) * | 2017-06-01 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
| US11242397B2 (en) | 2017-06-01 | 2022-02-08 | Pb Immune Therapeutics Inc. | Anti-CD40 antibody and methods for blocking CD40-CD40L signaling |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| JP7445977B2 (ja) * | 2018-01-29 | 2024-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒ２媒介性疾患及び障害の治療法 |
| CA3090322A1 (en) * | 2018-02-12 | 2019-08-15 | Diabetes-Free, Inc. | Improved antagonistic anti-human cd40 monoclonal antibodies |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN111763259B (zh) * | 2020-09-03 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗cd40抗体及其用途 |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| US20240343817A1 (en) * | 2021-07-14 | 2024-10-17 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibody that specifically recognizes cd40 and application thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| CN117229396A (zh) * | 2022-06-06 | 2023-12-15 | 普米斯生物技术(珠海)有限公司 | 抗cd40抗体及其用途 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| CA1341562C (en) | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| BE893016R (fr) | 1982-04-29 | 1982-08-16 | Amatucci Aldo | Turbine a vent |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
| US5700913A (en) | 1982-12-15 | 1997-12-23 | Ajinomoto Co., Inc. | Unglycosylated human interleukin-2 polypeptides |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4816440A (en) | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4745180A (en) | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4931544A (en) | 1986-09-04 | 1990-06-05 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0444210B1 (en) | 1989-09-21 | 1995-05-24 | Idemitsu Kosan Company Limited | Arylstyrene polymer and copolymer and process for preparing the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| WO1995023512A1 (en) | 1994-03-03 | 1995-09-08 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| IL133305A0 (en) | 1997-06-20 | 2001-04-30 | Biogen Inc | Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020006901A1 (en) | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| AU4057300A (en) | 1999-03-30 | 2000-10-16 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
| JP2003508016A (ja) | 1999-04-16 | 2003-03-04 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| CN100389821C (zh) | 1999-10-04 | 2008-05-28 | 希龙公司 | 稳定化的含多肽的液体药物组合物 |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU1590201A (en) * | 1999-11-09 | 2001-06-06 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2001083755A2 (en) * | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| WO2002028481A2 (en) * | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2466931A1 (en) * | 2001-11-26 | 2003-06-05 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| PT1684869E (pt) * | 2003-11-04 | 2011-09-16 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros relacionados com células b |
| EP2301575A1 (en) * | 2003-11-04 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for solid tumors expressing the CD40 cell-surface antigen |
| DK1684805T3 (da) * | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma |
| SI1682177T1 (sl) * | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije |
| RS53073B (sr) * | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| JP6039343B2 (ja) | 2012-10-04 | 2016-12-07 | キヤノン株式会社 | 電子機器、電子機器の制御方法、プログラム、記憶媒体 |
-
2004
- 2004-11-04 RS RS20130482A patent/RS53073B/sr unknown
- 2004-11-04 PL PL04810510T patent/PL1682180T3/pl unknown
- 2004-11-04 SI SI200431280T patent/SI1682180T1/sl unknown
- 2004-11-04 AT AT04810510T patent/ATE447412T1/de active
- 2004-11-04 AU AU2004287482A patent/AU2004287482B2/en not_active Ceased
- 2004-11-04 PL PL04810421T patent/PL1682178T3/pl unknown
- 2004-11-04 JP JP2006538514A patent/JP4765039B2/ja not_active Expired - Fee Related
- 2004-11-04 SI SI200431514T patent/SI1682178T1/sl unknown
- 2004-11-04 ES ES09075395T patent/ES2435410T3/es not_active Expired - Lifetime
- 2004-11-04 PL PL04810420T patent/PL1694360T3/pl unknown
- 2004-11-04 WO PCT/US2004/036958 patent/WO2005044294A2/en not_active Ceased
- 2004-11-04 EP EP04810421A patent/EP1682178B8/en not_active Expired - Lifetime
- 2004-11-04 CA CA2544853A patent/CA2544853C/en not_active Expired - Fee Related
- 2004-11-04 AU AU2004287879A patent/AU2004287879C1/en not_active Ceased
- 2004-11-04 DK DK04810510T patent/DK1682180T3/da active
- 2004-11-04 JP JP2006538513A patent/JP4746552B2/ja not_active Expired - Lifetime
- 2004-11-04 PL PL09075395T patent/PL2149585T3/pl unknown
- 2004-11-04 EP EP09075395.5A patent/EP2149585B1/en not_active Expired - Lifetime
- 2004-11-04 AT AT04810420T patent/ATE476448T1/de active
- 2004-11-04 EP EP10006780A patent/EP2255828A1/en not_active Withdrawn
- 2004-11-04 ZA ZA200604419A patent/ZA200604419B/xx unknown
- 2004-11-04 DE DE602004028037T patent/DE602004028037D1/de not_active Expired - Lifetime
- 2004-11-04 EP EP04810420A patent/EP1694360B1/en not_active Expired - Lifetime
- 2004-11-04 CN CN2004800390435A patent/CN1905897B/zh not_active Expired - Lifetime
- 2004-11-04 PT PT04810510T patent/PT1682180E/pt unknown
- 2004-11-04 KR KR1020067010885A patent/KR101403910B1/ko not_active Expired - Fee Related
- 2004-11-04 CN CN200480037489.4A patent/CN1938045B/zh not_active Expired - Lifetime
- 2004-11-04 AT AT04810421T patent/ATE473016T1/de active
- 2004-11-04 RS RSP-2010/0041A patent/RS51230B/sr unknown
- 2004-11-04 EP EP04810510A patent/EP1682180B1/en not_active Expired - Lifetime
- 2004-11-04 WO PCT/US2004/036957 patent/WO2005044306A2/en not_active Ceased
- 2004-11-04 DK DK09075395.5T patent/DK2149585T3/da active
- 2004-11-04 JP JP2006538540A patent/JP5019881B2/ja not_active Expired - Lifetime
- 2004-11-04 SG SG200808017-8A patent/SG148143A1/en unknown
- 2004-11-04 CA CA2544949A patent/CA2544949C/en not_active Expired - Fee Related
- 2004-11-04 SI SI200431525T patent/SI1694360T1/sl unknown
- 2004-11-04 WO PCT/US2004/037152 patent/WO2005044854A2/en not_active Ceased
- 2004-11-04 KR KR1020067010894A patent/KR101125127B1/ko not_active Expired - Fee Related
- 2004-11-04 DE DE602004028505T patent/DE602004028505D1/de not_active Expired - Lifetime
- 2004-11-04 EP EP10007970A patent/EP2248830A1/en not_active Withdrawn
- 2004-11-04 PT PT90753955T patent/PT2149585E/pt unknown
- 2004-11-04 PT PT04810420T patent/PT1694360E/pt unknown
- 2004-11-04 DK DK04810420.2T patent/DK1694360T3/da active
- 2004-11-04 HR HR20100066T patent/HRP20100066T1/hr unknown
- 2004-11-04 ES ES04810421T patent/ES2346977T3/es not_active Expired - Lifetime
- 2004-11-04 DK DK04810421.0T patent/DK1682178T3/da active
- 2004-11-04 PT PT04810421T patent/PT1682178E/pt unknown
- 2004-11-04 CA CA002544948A patent/CA2544948A1/en not_active Abandoned
- 2004-11-04 ES ES04810510T patent/ES2333971T3/es not_active Expired - Lifetime
- 2004-11-04 DE DE602004023961T patent/DE602004023961D1/de not_active Expired - Lifetime
-
2006
- 2006-04-26 IL IL175225A patent/IL175225A/en not_active IP Right Cessation
- 2006-06-05 EC EC2006006607A patent/ECSP066607A/es unknown
- 2006-06-05 MA MA29078A patent/MA28331A1/fr unknown
-
2010
- 2010-01-15 CY CY20101100045T patent/CY1110231T1/el unknown
- 2010-09-28 CY CY20101100869T patent/CY1110803T1/el unknown
- 2010-10-18 CY CY20101100931T patent/CY1110839T1/el unknown
- 2010-12-13 JP JP2010277537A patent/JP2011072317A/ja not_active Withdrawn
-
2011
- 2011-02-18 JP JP2011033969A patent/JP2011126900A/ja not_active Withdrawn
- 2011-02-25 JP JP2011040922A patent/JP2011105769A/ja not_active Withdrawn
- 2011-04-05 AU AU2011201529A patent/AU2011201529B2/en not_active Ceased
-
2012
- 2012-03-05 EC ECSP12006607 patent/ECSP12006607A/es unknown
-
2013
- 2013-11-13 HR HRP20131085TT patent/HRP20131085T1/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007512243A5 (enExample) | ||
| US12054557B2 (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer | |
| AU784971B2 (en) | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies | |
| JP2007513073A5 (enExample) | ||
| US9308256B2 (en) | Method of treating rheumatoid arthritis with an anti-IL-6R antibody | |
| JP2025016606A5 (enExample) | ||
| HRP20131085T1 (hr) | Uporaba antagonistiäśkih anti-cd40 monoklonskih antitijela | |
| US20170174781A1 (en) | Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia | |
| JP2004510752A5 (enExample) | ||
| JP6268097B2 (ja) | 固形腫瘍治療のための併用薬物療法 | |
| US12194095B2 (en) | Combinations and uses thereof | |
| RU2006105642A (ru) | Способы и композиции для повышения эффективности антител для лечебных целей с использованием соединений, потенциирующих nk-клетки | |
| JP2020527332A5 (enExample) | ||
| US12358983B2 (en) | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof | |
| RU2007134368A (ru) | Способы лечения лимфом с использованием сочетания химиотерапевтического средства и il-2, и, не обязательно, антител анти-cd20 | |
| JPWO2021183934A5 (enExample) | ||
| WO2012076688A1 (en) | Combination comprising a derivative of the family of the combretastatins and cetuximab | |
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| JP2005525317A5 (enExample) | ||
| JPWO2020222668A5 (enExample) | ||
| Chatzidionysiou | Advances in therapies for rheumatoid arthritis | |
| EA042623B1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| Reddy et al. | 2004 Highlights From: The 27th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2004 | |
| HK40027114A (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| HK40027114B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |